Cell and Gene Therapy Catapult

#Biotech #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

How strong is the UK’s advanced therapy sector?  

DDW Editor Reece Armstrong speaks to Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult, about the UK’s strong position in advanced therapies and what the challenges are for making the country competitive within pharma.   RA: Why does the UK have a strong in position in clinical research for advanced therapies? … Read More

#Exclusive Content

#Cell and gene therapy #Cell and Gene Therapy Catapult #Cellular Origins #Manufacturing #Resolution Therapeutics

Consortium tackles the challenge of scaling CGT manufacturing

Cellular Origins, the Cell and Gene Therapy Catapult (CGT Catapult), and Resolution Therapeutics have formed a consortium to deliver a fully automated, scalable cell therapy manufacturing platform.  The consortium has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency. Read More

#News

#Advanced Therapies #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

UK network to support innovation within advanced therapies

A new network aspires to create a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these treatments.   Cell and Gene Therapy Catapult (CGT Catapult) and the Birmingham Health Partners Centre for Regulatory Science and Innovation (CRSI)… Read More

#News

Human adenovirus
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Gene delivery

Cross-industry consortium to improve AAV formulation

The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation. AAV-based gene therapies are being developed to treat a broad range of inherited and chronic diseases and several of these therapies have already… Read More

#News

UK Department of Education
#Advanced Therapies #Cell and gene therapy #Cell and Gene Therapy Catapult #UK government

UK’s Education Secretary joins CGT Catapult to celebrate apprentices 

The UK’s Education Secretary Gillian Keegan attended a meeting with the Cell and Gene Therapy Catapult (CGT Catapult) to discuss the role of apprenticeships in the advanced therapies industry.  The meeting, which took place at Teesside University’s National Horizons Centre in Darlington during National Apprenticeship Week, highlighted how apprenticeships are… Read More

#News #Regulatory

UK
#Advanced Therapies #BioIndustry Association #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

UK maintains dominant global position in cell and gene therapy

The UK is cementing its position as a global leader in cell and gene therapy (CGT), according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline. The report reveals a robust sector with significant investment, the highest number of… Read More

#News #Trending News

Great British Pounds, Investment
#Cell and Gene Therapy Catapult #Funding #Holosphere #Innovate UK

£1m grant to create VR training platform for CGT professionals 

UK technology company FourPlus, along with collaborators Holosphere and the Cell and Gene Therapy Catapult, have been awarded funding from Innovate UK to create and test a mixed reality training platform that enables customised training delivery for pharmaceutical companies and healthcare.   The project is a £1… Read More

#News

#Cancer research #Cell and Gene Therapy Catapult #Cell therapy #Funding #Innovate UK #NK:IO

£1.6m awarded to progress ovarian cancer cell therapy

NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. The funding will support preclinical development, including development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult, whose mission is to support the UK’s cell and gene therapy industry. NK:IO… Read More

#Business & Investment #News

#Autolomous #Cell and gene therapy #Cell and Gene Therapy Catapult #Digitalisation #Funding

CGT grant funds implementation and digitisation of PAT  

Autolomous, a developer of critical manufacturing management systems for cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of CGTs, have been awarded a joint £1.2 million grant by UK Research and Innovation (UKRI),… Read More

#News

CGTC Edinburgh lab
#Cell and gene therapy #Cell and Gene Therapy Catapult #CGT Catapult #Edinburgh BioQuarter #Lab technology

Cell and Gene Therapy Catapult opens new Scottish laboratories 

The Cell and Gene Therapy Catapult (CGT Catapult) has opened its facility in the Edinburgh BioQuarter, its first site in Scotland.   By opening these new laboratories, the CGT Catapult aims to provide expertise, resources and technology to help cell therapy developers improve their manufacturing processes and navigate… Read More

#News

Cell and gene therapies
#Advanced Therapies #Cell and gene therapy #Cell and Gene Therapy Catapult

New CGT process analytical technologies lab opens

The Cell and Gene Therapy Catapult (CGT Catapult) has opened a new laboratory in Stevenage, UK, which has been specifically designed and equipped to allow cell and gene therapy (CGT) developers to monitor and control their advanced therapy manufacturing processes in real-time, to improve product quality and safety while… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Biopharma #Cell and gene therapy #Cell and Gene Therapy Catapult

Cell and gene therapy – where is the innovation? 

Where globally is innovation occurring and what factors - industry, regulatory, and academia - are helping developers get their products to market? Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy… Read More

#Exclusive Content

#Biomanufacturing #Cell and Gene Therapy Catapult #Cell therapy #Manufacturing

UK consortium looks to advance cell therapy manufacturing  

A new consortium has been launched in the UK to help drive innovation in the manufacturing of personalised cell therapies.  The consortium was launched by the Cell and Gene Therapy Catapult (CGT Catapult) and will be led by advanced therapy medicinal products (ATMP) developer Achilles Therapeutics. The… Read More

#News

Dementia
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Dementia

New partnership looks to gene therapy for dementia  

The Cell and Gene Therapy Catapult (CGT Catapult) has partnered with the UK Dementia Research Institute (UK DRI) to help advance the development of adeno-associated virus (AAV) based gene therapies for dementia.  Through the collaboration, the CGT Catapult will work with UK academic centres and the UK… Read More

#News

DNA vector
#Cell and gene therapy #Cell and Gene Therapy Catapult

Report sets out strategy for UK cell and gene therapy sector  

The Cell and Gene Therapy Catapult (CGT Catapult) has published recommendations on how the UK can continue to maintain its global advantage in the adoption of Advanced Therapy Medicinal Products (ATMPs).    The organisation’s ‘National Cell and Gene Therapy Vision for the UK’ outlines… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and Gene Therapy Catapult #Clinical trials

UK recognised as ATMP leader in clinical trials, report states

The UK has been highlighted as a leader in clinical trials for Advanced Therapy Medicinal Products (ATMPs), after a report published by the Cell and Gene Therapy Catapult (CGT Catapult) displayed the sector’s continued growth in the UK. The report CGT Catapult’s 2021 Advanced Therapy Medicinal Product (ATMP) report… Read More

#News